Patents Issued in June 12, 2007
-
Patent number: 7229948Abstract: The present invention involves an exhaust gas catalyst and method of manufacturing same. The invention provides for a cost-effective material which lowers the cold-start emissions from the exhaust of vehicles. The invention is a passive system which accelerates the light-off temperature of catalyst in a cost-effective fashion. The invention includes a method of manufacturing an exhaust gas catalyst capable of lowering cold-start emissions including the steps of providing an oxide mixture having praseodymium and cerium, doping about 0–10% weight zirconium and about 0–10% weight yttrium to the oxide mixture, adding about 0–2% weight metal including palladium, platinum, or rhodium to the oxide mixture, mixing gamma aluminum to the oxide mixture for washcoating and washcoating the oxide mixture onto a monolithic substrate.Type: GrantFiled: January 24, 2005Date of Patent: June 12, 2007Assignee: Ford Global Technologies, LLCInventors: Albert Nazipovich Chigapov, George Wade Graham, Haren Sakaral Gandhi, Hung-Wen Jen
-
Patent number: 7229949Abstract: A safe delivery system of agriculturally active material is formed using an encapsulation process. A microencapsulated suspension of agriculturally active material includes an encapsulating agent formed from a graft copolymer of starch and at least one vinyl monomer.Type: GrantFiled: June 29, 2005Date of Patent: June 12, 2007Assignee: United Phosphorus, Ltd.Inventors: Prakash Mahadev Jadhav, Jaidev Rajnikant Shroff
-
Patent number: 7229950Abstract: A method of treating a hydrocarbon containing formation is described. The method may include providing a hydrocarbon recovery composition to the hydrocarbon containing formation. Hydrocarbons in the hydrocarbon containing formation may interact with the hydrocarbon recovery composition. The hydrocarbon recovery composition may include an aliphatic anionic surfactant and an aliphatic nonionic additive. In some embodiments, an aliphatic anionic surfactant may be branched. In other embodiments, an aliphatic nonionic additive may be branched.Type: GrantFiled: April 20, 2006Date of Patent: June 12, 2007Assignee: Shell Oil CompanyInventors: Paul Gregory Shpakoff, Kirk Herbert Raney
-
Patent number: 7229951Abstract: Organo-Imino molybdenum complexes are disclosed having the formula Z2N2MOS4C2N2R4 wherein Z and R are independently selected from the group consisting of linear hydrocarbon groups, branched hydrocarbon groups, cyclic hydrocarbon groups, and mixtures thereof. The compounds are useful as friction modifiers in lubricants.Type: GrantFiled: July 18, 2001Date of Patent: June 12, 2007Assignee: Crompton CorporationInventors: Cyril A. Migdal, Paul E. Stott, Nikolai Aleksandrovich Ustynyuuk, Dmitry Nikolaievich Zaroubine, Ilia Victorovich Yampolsky, Konstantin Aleksandrovich Rufanov
-
Patent number: 7229952Abstract: An additive package for removing oil from solid material recovered from a well bore, e.g., drill cuttings and produced sand, is provided. The additive package includes an aqueous acidic solution containing a polymer substituted with an amino group, a halogenating agent, and optionally one or more surfactants. The polymer substituted with an amino group is preferably chitosan, and the halogenating agent is preferably a sodium hypochlorite solution. A product of the reaction of the polymer and the halogenating agent, in conjunction with the surfactant when present, is capable of causing the separation of at least a portion of the oil from the solid material.Type: GrantFiled: June 23, 2004Date of Patent: June 12, 2007Assignee: Halliburton Energy Services, Inc.Inventors: B. Raghava Reddy, Sears T. Dealy, Ian D. Robb
-
Patent number: 7229953Abstract: A process of stripping a coating according to the invention comprises subjecting a coated substrate to an aqueous medium containing a peroxide and an interfacial mixing agent, and to heating preferably by either ultraviolet (UV) and/or infrared (IR) radiation. The substrate is completely stripped of the coating and suffers no damage to itself as a result of the paint debonding/dislodging process. No toxic wastes are generated from this process, nor are particulates associated with air pollution generated. The metal substrates being stripped also do not undergo corrosion or other damage as a result of the described process.Type: GrantFiled: October 25, 2005Date of Patent: June 12, 2007Assignee: Green Oaks Research Laboratories, Inc.Inventors: Vinod S. Agarwala, Prithviraj Pole, Krishnan Rajeshwar
-
Patent number: 7229954Abstract: A carpet cleaning composition comprises a terpene hydrocarbon solvent that also functions as a fragrance, one or more surfactants, an anti-soil component, an anti-stain component, water, and, optionally, an anti-foam agent and a pH adjusting agent. In the preferred embodiment, the terpene hydrocarbon solvent is d-limonene, an organic, low volatility solvent produced from citrus oil extract. The pH adjusting agent maintains a pH in the carpet cleaning composition between 8.5 and 9.5 and preferably about 9.0.Type: GrantFiled: January 9, 2004Date of Patent: June 12, 2007Assignee: Bissell Homecare, Inc.Inventor: Jesse J. Williams
-
Patent number: 7229955Abstract: A composition in a water-soluble pouch, the pouch comprises at least two compartments, and each compartment contains a different component of the composition, wherein a first compartment contains a first component and the first component comprises a liquid matrix and a source of peracid.Type: GrantFiled: August 26, 2005Date of Patent: June 12, 2007Assignee: The Procter & Gamble CompanyInventors: Bruno Matthieu Dasque, Nicola Ethel Davidson, Francesco de Buzzaccarini, James Charles Theophile Roger Burckett-St. Laurent, Valerio Del Duca, Frank William DeNome
-
Patent number: 7229956Abstract: Wipes are described, premoistened with an anti-static amphoteric cleaning composition. In tests for residual surface charge wipes of the invention showed remarkable charge dissipation properties. Also described are packaged products containing such wipes, use of such wipes in cleaning a surface and the manufacture of such wipes and packaged products.Type: GrantFiled: September 25, 2001Date of Patent: June 12, 2007Assignee: Reckitt Benckiser (UK) LimitedInventors: David Bedford, Julie Brennan
-
Patent number: 7229957Abstract: This invention provides the following: an amphiphilic functional substance with lipophilicity, affinity for supercritical CO2, and if necessary hydrophilicity comprising an oligoolefin chain and a perfluoroalkyl group(s) at a single end thereof or at both ends thereof with or without the intervention of a poly(oxyalkylene) chain, which enables the utilization of supercritical CO2 as a reaction medium; a photopolymerizable functional substance comprising an oligoolefin chain and a reversible photopolymerization/dissociation group(s) at a single end thereof or at both ends thereof and a functional substance comprising a photo- and/or thermodissociable polymer obtained by photopolymerization of the aforementioned photopolymerizable functional substance, which can be utilized as recycle polymers; a hydrolyzable functional substance comprising a polymer obtained by chain-elongating plural oligoolefin chains through ester linkages, which can be utilized as a recycle polymer; and a functional substance capable of foType: GrantFiled: May 25, 2006Date of Patent: June 12, 2007Assignee: San-El Kougyou CorporationInventor: Takashi Sawaguchi
-
Patent number: 7229958Abstract: Organopolysiloxanes which contain a fragrance alcohol Y—OH bonded via a betaine ester group having the structure —N+R1R2—CH2—C(O)OY, cleave off the fragrance alcohol under acid conditions and are resistant to hydrolysis in the neutral and weakly basic range. The organopolysiloxanes adhere to textile fibres, skin or hair and are suitable as perfume components for textile treatment agents and personal care products.Type: GrantFiled: June 6, 2006Date of Patent: June 12, 2007Assignee: Degussa AGInventors: Hans-Jürgen Köhle, Thomas Salomon, Ronald Smith
-
Patent number: 7229959Abstract: This invention provides supplemented and unsupplemented tissue sealants as well as methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one antibody. The composition may be further supplemented with, for example, one or more analgesics, antimicrobial compositions, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.Type: GrantFiled: June 7, 1995Date of Patent: June 12, 2007Assignee: The American National Red CrossInventors: William N. Drohan, Martin J. MacPhee, Hernan Nunez, Gene Liau, Wilson H. Burgess, Thomas Maciag
-
Patent number: 7229960Abstract: The invention provides methods and compositions for treating subjects using Grb7 antagonists. Specifically disclosed are Grb7 antagonists that bind selectively to Grb7 and interfere with the ability of Grb7 to bind to its native ligands. These compositions are useful in the prevention and treatment of disorders characterized by abnormal interaction of Grb7 with its native ligands (e.g., ErbB2).Type: GrantFiled: November 5, 2001Date of Patent: June 12, 2007Assignee: University of Vermont and State Agricultural CollegeInventors: Stephanie C. Pero, David N. Krag, Lyn Oligino
-
Patent number: 7229961Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:86).Type: GrantFiled: February 25, 2002Date of Patent: June 12, 2007Assignee: Cellgate, Inc.Inventors: Jonathan B. Rothbard, Paul A. Wender, P. Leo McGrane, Lalitha V. S. Sista, Thorsten A. Kirschberg
-
Patent number: 7229962Abstract: Disclosed are concatameric proteins comprising two soluble domains, in which the C-terminus of a soluble domain of a biologically active protein is linked to the N-terminus of an identical soluble domain or a distinct soluble domain of a biologically active protein. Also, the present invention discloses dimeric proteins formed by formation of intermolecular disulfide bonds at the hinge region of two monomeric proteins formed by linkage of a concatamer of two identical soluble extracellular regions of proteins involving immune response to an Fc fragment of an immunoglobulin molecule, their glycosylated proteins, DNA constructs encoding the monomeric proteins, recombinant expression plasmids containing the DNA construct, host cells transformed or transfected with the recombinant expression plasmids, and a method of preparing the dimeric proteins by culturing the host cells. Further, the present invention discloses pharmaceutical or diagnostic compositions comprising the dimeric protein or its glycosylated form.Type: GrantFiled: July 26, 2002Date of Patent: June 12, 2007Assignee: Medexgen Co., Ltd.Inventors: Yong-Hoon Chung, Ji-Woong Han, Hye-Ja Lee, Eun-Yong Choi, Jin-Mi Kim
-
Patent number: 7229963Abstract: A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organsism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition.Type: GrantFiled: October 17, 2002Date of Patent: June 12, 2007Assignees: United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health, The Salk Institute for Biological StudyInventors: Vittorio Sartorelli, Pier Lorenzo Puri
-
Patent number: 7229964Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the ?-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.Type: GrantFiled: July 16, 2003Date of Patent: June 12, 2007Assignee: Novo Nordisk A/SInventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
-
Patent number: 7229965Abstract: The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human growth hormone, for the manufacturing of a medicament useful for increasing insulin sensitivity in low dose therapy. The patient is preferably a normal subject, i.e. not growth hormone deficient patient and/or a non-obese patients. By low dose therapy is preferably meant less than 0.008 mg/kg/day, preferably 0.007 mg/kg/day or less, more preferably 0.005 mg/kg/day or less and most preferably 0.003 mg/kg/day or less. The therapy is preferably performed during short term treatment, preferably less than one month.Type: GrantFiled: January 21, 2004Date of Patent: June 12, 2007Assignee: Pharmacia ABInventor: David B Dunger
-
Patent number: 7229966Abstract: Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.Type: GrantFiled: February 17, 2004Date of Patent: June 12, 2007Assignee: Nastech Pharmaceutical Company Inc.Inventors: Steven C. Quay, Gordon Brandt, Mary S. Kleppe, Conor J. MacEvilly
-
Patent number: 7229967Abstract: The compositions described herein comprise oxygenated albumin in an aqueous sterile physiological or serum solution. The albumin is oxygenated to increase the oxygen content up to O2 saturation with clinically useful oxygen gas. The preferred oxygen-saturated preparations, containing albumin in concentrations from about 5% w/v to about 25% w/v, are useful as clinical resuscitation preparations that release oxygen in a pattern similar to the release of oxygen by whole blood.Type: GrantFiled: November 12, 2004Date of Patent: June 12, 2007Assignee: Hunter Research CorporationInventor: Bernard V. Ecanow
-
Patent number: 7229968Abstract: A pharmaceutical composition comprising peptide AG73 Arg-Lys-Arg-Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr (SEQ ID NO:1).Type: GrantFiled: December 3, 2004Date of Patent: June 12, 2007Assignee: University of WashingtonInventors: Gerardo Castillo, Alan D. Snow
-
Patent number: 7229969Abstract: Combination of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same substrate specificity (DP IV-analogous enzymatic activity) and inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) and of enzymes having the same substrate specificity (APN-analogous enzymatic activity) for a more than additive to superadditive inhibition for the treatment of arteriosclerosis, for the treatment of allergic reactions of the type I according to the Gell and Coombs classification and for the treatment of dermatological diseases with follicular and epidermal hyperkeratoses and an enhanced proliferation of keratinocytes.Type: GrantFiled: December 21, 2001Date of Patent: June 12, 2007Assignee: IMTM GmbHInventors: Siegfried Ansorge, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Robert Vetter, Harald Gollnick
-
Patent number: 7229970Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: May 13, 2005Date of Patent: June 12, 2007Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Susan Ashwell, Reinhardt B. Baudy, Louis J. Lombardo
-
Patent number: 7229971Abstract: This invention relates to a method for regulating the biodegradability of composite biomaterials comprising calcium salt (particularly hydroxyapatite) and collagen, improved composite biomaterials obtained via such method, and a method for increasing bone mass with the use of such composite biomaterials.Type: GrantFiled: September 10, 2004Date of Patent: June 12, 2007Assignees: Japan Science and Technology Agency, National Institute for Materials Science, Nitta Gelatin Inc.Inventors: Junzo Tanaka, Masanori Kikuchi, Noriichi Ito, Yoshinobu Mandai, Hiroko Matsumoto, Yoshihisa Koyama, Kazuo Takakuda
-
Patent number: 7229972Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.Type: GrantFiled: December 7, 2004Date of Patent: June 12, 2007Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Datong Tang, Yonghua Gai, Ying Sun, Guoyou Xu, Zhe Wang
-
Patent number: 7229973Abstract: Mixed micelles containing poly(L-histidine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers exhibiting multidrug resistance. Targeting ligands, such as folate, can also be attached to the mixed micelles for enhancing drug delivery into cells. Methods of making poly(L-histidine), synthetic intermediates, and block copolymers are also described.Type: GrantFiled: May 19, 2003Date of Patent: June 12, 2007Inventors: You Han Bae, Kun Na, Eun Seung Lee
-
Patent number: 7229974Abstract: Oligonucleotides of the formula 5?-(CAP)-(Oligo)-(CAP)-3? are disclosed where (oligo) is a nucleotide sequence of from 10 to 40 nucleotides in length, and CAP is Gm, where m is an integer of from zero to ten, the two CAP's which are present in the molecule can be defined independently of each other and must be different in the case where m is zero at the 5? or 3? end and the end of the Oligo sequence is other than guanine. The oligonucleotides can be synthesized chemically. The oligonucleotides are used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors.Type: GrantFiled: May 21, 2001Date of Patent: June 12, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Anuschirwan Peyman, Eugen Uhlmann
-
Patent number: 7229975Abstract: Nucleic acid, including DNA, immunization is used to generate a protective immune response in a host, including humans, to a serine-threonine kinase (STK) of a strain of Chlamydia. A non-replicating vector, including a plasmid vector, contains a nucleotide sequence encoding a STK or a fragment of the STK that generates antibodies that specifically react with STK and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the STK in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for in vivo administration to the host.Type: GrantFiled: September 21, 2000Date of Patent: June 12, 2007Assignee: University of ManitobaInventor: Robert C. Brunham
-
Patent number: 7229976Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.Type: GrantFiled: September 25, 2003Date of Patent: June 12, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter
-
Patent number: 7229977Abstract: The invention is concerned with film-forming compositions containing hydrolysates of the exopolysaccharide YAS34 for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules.Type: GrantFiled: June 15, 2004Date of Patent: June 12, 2007Assignee: Warner-Lambert CompanyInventors: Robert Anthony Scott, Dominique Cade, Xiongwei He
-
Patent number: 7229978Abstract: A process for making water-soluble phosphonooxymethyl ethers of hindered alcohol and phenol containing pharmaceuticals, such as camptothecin, propofol, etoposide, Vitamin E and Cyclosporin A.Type: GrantFiled: December 20, 2002Date of Patent: June 12, 2007Assignee: MGI GP, Inc.Inventors: George Bonneville, Greg Delahanty, Andrew J. Walz
-
Patent number: 7229979Abstract: Methods of treating a host suffering from restenosis are provided. The methods include delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The methods further include the administration of a chemotherapeutic agent in combination with delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The chemotherapeutic agent may be coated on the stent or administered systemically.Type: GrantFiled: June 23, 2004Date of Patent: June 12, 2007Assignee: Immune Modulation, Inc.Inventors: Emeka J. Nchekwube, Emmanuel A. Ojo-Amaize, Howard B. Cottam
-
Patent number: 7229980Abstract: Disclosed herein is a paroxetine cholate or cholic acid derivative salt and a composition comprising paroxetine and cholic acid or a derivative thereof. Further disclosed is a pharmaceutical composition comprising the paroxetine salt or the composition. The pharmaceutical composition can be formulated into an oral preparation for swallowing without water as an orally disintegrating tablet for paroxetine.Type: GrantFiled: January 31, 2005Date of Patent: June 12, 2007Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Sang Joon Lee, Hee Jong Shin, Min Hyo Ki, Su Kyoung Lee, Bok Young Kim, Hong Woo Lee
-
Patent number: 7229981Abstract: The invention relates to a novel process for the preparation of an aminoalcohol of the formula racemically or optically active, starting from 2-azabi-cyclo[2.2.1]hept-5-en-3-one, its further conversion to give the corresponding acyl derivative and its further conversion to (1S,4R)— or (1R,4S)-4-(2-amino-6-chloro-9-H-purine-9-yl)-2-cyclopentenyl-1-methanol of the formulae In the latter synthesis, the aminoalcohol is converted into the corresponding D- or L-tartrate, which is then reacted with N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide of the formula to give (1S, 4R)- or (1R, 4S)-4-[(2-amino-6-chloro-5-formamido-4-pyrimidinyl)amino]-2-cyclopentenyl-1-methanol of the formulae and then cyclized to give the end compounds.Type: GrantFiled: October 29, 2003Date of Patent: June 12, 2007Assignee: Lonza AGInventors: Walter Brieden, Josef Schröer, Christine Bernegger-Egli, Eva Maria Urban, Michael Petersen, Jean-Paul Roduit, Katja Berchtold, Holger Breitbach
-
Patent number: 7229982Abstract: The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.Type: GrantFiled: July 22, 2003Date of Patent: June 12, 2007Inventors: William D. Moore, Shaun Fitzpatrick, Christian Seiler, Robert Saklatvala, Catherine R. Petts
-
Patent number: 7229983Abstract: The present invention relates to novel, low molecular weight broad spectrum compounds in particular to a class of 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid or their derivatives which have ?-lactamase inhibitory and antibacterial properties. The compounds are therefore useful in the treatment of antibacterial infections in humans or animals, either alone or in combination with other antibiotics.Type: GrantFiled: April 28, 2004Date of Patent: June 12, 2007Assignee: Wyeth Holdings CorporationInventors: Tarek Suhayl Mansour, Aranapakam Mudumbai Venkatesan
-
Patent number: 7229984Abstract: Compounds of the Formula I: wherein m, n, k, A, X, Y, Z, Ar, R1, R2, R3, and R4 are as defined herein. The compounds are useful as 5-HT6 receptor antagonists. Also provided are compositions comprising, methods of using, and methods of making the subject compounds.Type: GrantFiled: December 9, 2005Date of Patent: June 12, 2007Assignee: Roche Palo Alto LLCInventors: Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
-
Patent number: 7229985Abstract: Disclosed are 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous and possesses improved absorption and dissoluvability, and a pharmaceutical composition comprising the same. Also disclosed are processes for producing 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine, which has been rendered amorphous, and a pharmaceutical composition comprising the same.Type: GrantFiled: December 25, 2002Date of Patent: June 12, 2007Assignee: Meiji Seika Kaisha, Ltd.Inventors: Toyoaki Ishikura, Takayuki Ishizawa, Kenji Suemune, Mayumi Ishiwata, Chikako Udagawa
-
Patent number: 7229986Abstract: A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.Type: GrantFiled: May 15, 2001Date of Patent: June 12, 2007Assignee: Takeda Pharmaceutical Company Ltd.Inventors: Yuji Ishihara, Jun Terauchi, Nobuhiro Suzuki, Shiro Takekawa, Kazuyoshi Aso
-
Patent number: 7229987Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.Type: GrantFiled: May 6, 2003Date of Patent: June 12, 2007Assignee: Eli Lilly and CompanyInventors: Jochen Ammenn, James Ronald Gillig, Lawrence Joseph Heinz, Philip Arthur Hipskind, Michael Dean Kinnick, Yen-Shi Lai, John Michael Morin, Jr., James Arthur Nixon, Carsten Ott, Kenneth Allen Savin, Theo Schotten, Lawrence John Slieker, Nancy June Snyder, Michael Alan Robertson
-
Patent number: 7229988Abstract: The present invention provides novel dialkylhydroxybenzoic acid derivatives containing metal chelating groups and the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species and/or excess Zn ions, in particular stroke, Parkinson's disease, Alzheimer's disease. The compounds of the invention have not only low toxicity but also similar or superior LPO inhibition activity to references. They also effectively inhibit the cerebral neuronal cell death by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.Type: GrantFiled: June 5, 2003Date of Patent: June 12, 2007Assignee: Samsung Electronics Co., Ltd.Inventors: Eu-Gene Oh, Sung-Bo Ko, Kyung-Hwa Kim, In-Kyu Chang, Dennis W. Choi, Laura L. Dugan, Jae-Young Koh, In-Jae Shin, Moo-Ho Won
-
Patent number: 7229989Abstract: Photochromic 3H-naphtho[2,1-b]pyran compounds corresponding to formula I in which the groups R1 to R7 and B? have defined meanings and the use of such photochromic compounds in synthetic resin articles of all types, particularly for ophthalmic purposes. The photochromic 3H-naphtho[2,1-b]pyran derivatives have particularly long-waved absorption maxima in the open form, and when used in photochromic eyeglass lenses, produce essentially blue color tones which have a high darkening capacity.Type: GrantFiled: September 21, 2004Date of Patent: June 12, 2007Assignee: Rodenstock GmbHInventors: Claudia Mann, Manfred Melzig, Udo Weigand
-
Patent number: 7229990Abstract: A bicyclic heteroaromatic compound according to general formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is (3–8C)cycloalkyl, (2–7C)heterocycloalkyl, (6–14C)aryl or (4–13C)heteroaryl; all optionally substituted with one or more substituents; R2 is (1–4C)alkyl, (2–4C)alkenyl, (2–4C)alkynyl, (6–14C)aryl or (4–13C)heteroaryl; R3 is (1–8C)alkyl, (3–8C)cycloalkyl, (2–7C)heterocycloalkyl, (6–14C)aryl or (4–13C)heteroaryl; Y is CH or N; Z is NH2 or OH; A is S, N(H), N(R), O or a bond and B is N(H), O or a bond; X1—X2 is C?C, C(O)—NH, NH—C(O), C(O)—O, O—C(O), C?N, N?C or S or O. The compounds of the invention can be used in fertility regulation therapies.Type: GrantFiled: September 17, 2001Date of Patent: June 12, 2007Assignee: N.V. OrganonInventors: Cornelis Marius Timmers, Willem Frederik Johan Karstens
-
Patent number: 7229991Abstract: 5-aminomethyl-1H-pyrrole-2-carboxylic acid amide compounds corresponding to formula I and processes for the production thereof. Pharmaceutical preparations containing these compounds and the use of these compounds for the production of pharmaceutical preparations and in related treatment methods.Type: GrantFiled: June 20, 2005Date of Patent: June 12, 2007Assignee: Gruenenthal GmbHInventors: Beatrix Merla, Corinna Sundermann, Utz-Peter Jagusch, Werner Englberger, Hagen-Heinrich Hennies, Babette-Yvonne Kögel
-
Patent number: 7229992Abstract: (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine dihydrochloride is obtained by debenzylating (2R)-4-benzyl-1-[3,5-bis(trifluoromethyl)-benzoyl]-2-(3-hydroxy-4-methylbenzyl)piperazine, then N-alkylating and converting to hydrochloride.Type: GrantFiled: June 8, 2001Date of Patent: June 12, 2007Assignee: Astellas Pharma Inc.Inventors: Keiichi Koga, Ryoki Orii, Yosuke Fujii, Shunsuke Goto, Satoshi Hirabayashi
-
Patent number: 7229993Abstract: This invention relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel aryl-substituted pyrimidine compounds of Formula I: or a pharmaceutically acceptable salt, or solvate thereof, wherein A, R1, R2, R3 and R4 are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.Type: GrantFiled: March 13, 2003Date of Patent: June 12, 2007Assignee: Euro-Celtique S.A.Inventors: R. Richard Goehring, Sam F. Victory, Donald J. Kyle
-
Patent number: 7229994Abstract: Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, and pyridine N-oxide; R2 is independently selected from ethyl and isopropyl; R3 is independently selected from hydrogen and fluoro; R4 is independently selected from —OH, —NH2 and —NHSO2R5; and R5 is independently selected from hydrogen, —CF3 and C1–C6 alkyl, or salts thereof or separate enantiomers and salts thereof; where each R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1–C6 alkyl, NO2, CF3, C1–C6 alkoxy, chloro, fluoro, bromo, and iodo.Type: GrantFiled: May 16, 2002Date of Patent: June 12, 2007Assignee: AstraZeneca ABInventors: William Brown, Christopher Walpole, Niklas Plobeck
-
Patent number: 7229995Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein n, R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6 and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.Type: GrantFiled: November 1, 2005Date of Patent: June 12, 2007Assignee: Neurocrine Biosciences, Inc.Inventors: Charles Q. Huang, Chen Chen, Yongsheng Chen, Zhiqiang Guo, Warren Wade, Martin Rowbottom, Jaimie K. Rueter
-
Patent number: 7229996Abstract: Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.Type: GrantFiled: July 21, 2005Date of Patent: June 12, 2007Assignee: Cumbre Pharmaceuticals Inc.Inventors: Zhenkun Ma, Jing Li, Susan Harran, Yong He, Keith P. Minor, In Ho Kim, Charles Z. Ding, Jamie C. Longgood, Yafei Jin, Keith D. Combrink
-
Patent number: 7229997Abstract: Compounds of the general formula (I): wherein R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament which particularly acts on the central nervous system, particularly for use as anti-obesity agents.Type: GrantFiled: May 16, 2003Date of Patent: June 12, 2007Assignee: Biovitrum ABInventors: Björn M. Nilsson, Erik Ringberg